ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
0.410
+0.010 (2.50%)
Aug 28 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.40 - 0.43
52 week 0.35 - 1.04
Open 0.41
Vol / Avg. 188,120.00/608,046.00
Mkt cap 37.00M
P/E     -
Div/yield     -
EPS -0.12
Shares 90.25M
Beta 0.75
Inst. own 15%
Nov 9, 2015
Q3 2015 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 6, 2015
Q2 2015 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
Aug 6, 2015
Q2 2015 ImmunoCellular Therapeutics Ltd Earnings Release
Jul 8, 2015
ImmunoCellular Therapeutics Ltd at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 26, 2015
ImmunoCellular Therapeutics Ltd Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -36.08% -34.66%
Return on average equity -40.94% -37.69%
Employees 4 -
CDP Score - -

Address

23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company's cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Company's lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters